Purpose: Robot-assisted surgery has been rapidly adopted in the U.S. for prostate cancer. Its adoption has been driven by market forces and patient preference, and debate continues regarding whether it offers improved outcomes to justify the higher cost relative to open surgery. We examined the comparative effectiveness of robot-assisted vs open radical prostatectomy in cancer control and survival in a nationally representative population. Accepted for publication September 8, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
PROSTATE cancer is the most common solid organ tumor in the U.S. and UK with an estimated incidence of 220,800 in the U.S. and 42,000 in the UK. 1, 2 More than 27,500 people in the U.S. die of PCa annually. 1 Radical prostatectomy remains the most common treatment for clinically localized PCa. In addition, RARP was rapidly adopted after it was introduced in 2000, and since 2008 has comprised the majority of radical prostatectomies performed in the U.S. 3 Similarly, the use of RARP is growing in the UK with 43% of all trusts conducting radical prostatectomy offering this procedure. 4 Compared to ORP, RARP is associated with lower intraoperative blood loss, fewer transfusions, complications, anastomotic strictures, perioperative mortality and shorter length of hospital stay. 3 However, it remains significantly more costly than ORP. 5 The intermediate-term evidence for RARP is limited as no comparative effectiveness studies to date have accrued intermediate term followup. This is noteworthy in light of claims that tactile feedback during ORP, which is lacking during robot-assisted surgery, enables intraoperative decision making that reduces positive surgical margins and, thus, improves long-term cancer control. 6 Studies have been inconclusive in comparing cancer control and the need for additional cancer therapy between surgical approaches. 7e9 In this study we determined the comparative effectiveness of RARP vs ORP in terms of primary outcomes of additional cancer therapy, and all cause and prostate cancer specific mortality in a nationally representative cohort.
METHODS

Population Source
The observational cohort study was comprised of the recent release of the SEER-Medicare linked database, covering SEER up to 2011, Medicare claims to 2012 and survival outcomes to 2013. SEER identifies 28% of incident cancer cases in the U.S. and Medicare insures approximately 97% of Americans age 65 years or older. The study was approved by the Weill Cornell Medical College institutional review board (protocol no. 1409015491).
Study Population
Men who underwent ORP vs RARP between 2003 and 2012, whose procedures were performed within 1 year of the primary diagnosis of PCa, were selected based on CPT procedure codes 55866 (RARP) vs 55840, 55842 and 55845 (ORP). To assure that patient followup records were captured in the database, men who were not continuously enrolled in Medicare Part A and B, or were enrolled in a health maintenance organization during the year preceding the procedure and during the study interval, were excluded from analysis. Additionally, those with prior cancers, those who received radiation or ADT before prostatectomy, those not linked to SEER, without hospitalization records or clinical or pathological stage were excluded ( fig. 1 ).
Covariates
Year of treatment, age at treatment, race, ethnicity, population density, marital status, U.S. region, histology, combined T stage, N stage and tumor grade were assigned for each subject. 10 Census tract socioeconomic status was determined using quartiles of median household income and percentage of individuals with high school diplomas. Patient comorbidity was assessed based on prior year encounters in inpatient, outpatient, office and home health settings. They were determined using ICD-9 coding algorithms created and validated for use with administrative data 11 with the addition of acute myocardial infarction, coronary artery and cerebrovascular disease. Surgeon volume was determined based on quartiles. Unknown categories were created for race, ethnicity, marital status, T and N stage, cancer grade and SEER regions when patients had missing characteristics.
Outcomes
Overall survival was determined as the time from procedure to all cause mortality, with subjects censored at the end of followup for survival data (December 31, 2013). For cancer specific survival, subjects were further censored at the time of noncancer related death, determined by the cause of death provided in SEER. Freedom from additional treatment included time from surgery until ADT or radiation therapy. Men were censored at time of death for any cause or end of followup for encounter data (December 31, 2012). The use of post-prostatectomy radiation and/or ADT was captured consistent with prior studies. 3 Followup time was determined using the censoring distribution (supplementary table 1, http://jurology.com).
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Statistical Analyses
Due to potential differences in men undergoing ORP and RARP, propensity score matching was performed. Propensity score matching is used in observational studies to select control subjects who are matched with treated subjects on controlled background covariates which, left uncontrolled for, may lead to biased estimates of treatment effects. 13 Propensity scores were computed using logistic regression models for the probability of undergoing RARP, including all available demographic, hospital and cancer related variables found to be associated with an outcome of interest. Then one-to-one nearest neighbor matching was performed to pair observations with a similar propensity for exposure within a specific limited range or caliper.
14 In this case the logit of the propensity score and a caliper of 0.25 times the standard deviation were used. 15 Subsequently, covariate balance between matched groups was examined using post-match c-statistic and standardized difference.
16,17 Overall 6,430 RARPs and 9,161 ORPs were included in the entire cohort, and 4,164 pairs of patients were included after applying propensity scores ( fig. 1 ). The cohort was considered balanced regarding known confounding variables with a post-match c-statistic of 0.527 and all standardized differences well below 10% (maximum 6.8%) (supplementary tables 2 and 3, http://jurology.com/).
Kaplan-Meier charts illustrate survival outcomes in full and paired cohorts and Cox proportional hazard models are used to estimate hazard ratios. We also examined sensitivity to inclusion of additional therapies as time varying covariates in the survival models as well as the inclusion of cancer grade. Hospital level clustering and the propensity matched study design were accounted for with marginal model analysis and sandwich covariance matrix estimation. 18 All analyses were performed using SASÒ version 9.3.
RESULTS
We examined 15,591 men undergoing prostatectomy for PCa from 2003 to 2012. RARP accounted for 41.2% of radical prostatectomies during the 
DISCUSSION
This study is the first to our knowledge that demonstrates improved treatment-free survival associated with RARP vs ORP in the intermediate to long-term setting. We found that RARP all cause mortality and prostate cancer specific mortality are similar compared to ORP. The advent of robotassisted surgery has been criticized due to directto-consumer advertising, higher costs, hidden risks and the absence of level 1 evidence demonstrating significantly better outcomes. However, in the presence of significantly higher costs, 5, 27 the clinical importance of lower blood loss, which does not necessitate transfusion, 28 is questionable. Assurance of longer term survival is critical in light of these controversies and there is only 1 study to date that demonstrates acceptable long-term biochemical recurrence-free, metastasisfree and cancer specific survival at 10 years with rates of 73.1%, 97.5% and 98.8%, respectively. 29 However, there was no direct comparison with ORP and findings from this high volume referral center may not be generalizable to other health care settings.
Our study fills a critical gap in evidence as we observed similar prostate cancer specific mortality with a median followup of 6.5 years (IQR 5.1e7.9). Given the high prevalence of PSA screening in Western countries with a resultant lead time bias, our study's prostate cancer specific mortality is correspondingly low and should be reassuring for patients older than age 65. Longer term comparative effectiveness studies are needed to determine benefits in younger men. In the SPG4 (Scandinavian Prostate Cancer Group Study Number 4) and the PIVOT (Prostate Cancer Intervention Versus Observation Trial) 12 and 15-year followup was needed to reveal a relatively small absolute difference in prostate cancer specific mortality between watchful waiting and radical prostatectomy. 30 ,31 We also found that RARP is associated with lower use of additional radiation and ADT. One prior study using a 5% sample of Medicare beneficiaries during the early adoption of RARP from 2003 through 2005 demonstrated greater use of additional cancer therapy within 6 months of RARP vs ORP. 9 However, studies from tertiary referral centers have been inconclusive in determining the superiority of any 1 approach for other oncologic outcomes. For instance, a study of the National Cancer Database demonstrated that more lymph nodes are removed during ORP vs RARP.
32 However, the role of lymph node dissection during radical prostatectomy remains controversial, with a recent study suggesting that the number of lymph node dissections needed to avoid 1 prostate cancer specific death varies from 80 to 800, based on the current incidence of lymph node metastases.
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More recently Hu et al demonstrated that RARP was associated with fewer positive surgical margins compared to ORP and less use of additional cancer therapy (ADT and/or radiation therapy) within 2 years of RARP. 7 Our current study validates and extends these findings with up to a median 6.5 years of followup, demonstrating more durable cancer control benefits for RARP than ORP. Moreover, additional postprostatectomy radiation therapy is burdensome, associated with worse urinary and bowel function, poorer quality of life 34 and higher costs. 35 For instance, additional health care cost within 1 year of PCa diagnosis and radical prostatectomy was $1,361 for ADT alone, $12,040 for additional radiotherapy and $23,487 for radiotherapy with ADT. Therefore, while RARP is more costly than ORP upfront, this is offset by less subsequent use of additional cancer therapy, and associated direct and indirect costs of treating the complications of adjuvant radiation and/or ADT.
Finally, RARP was associated with noninferior overall survival compared to ORP in men who were older than age 65. This finding is noteworthy given that men undergoing RARP had more comorbidities before propensity matching and residual confounding related to observed factors might favor ORP. Additional residual confounding related to unobserved differences in our treatment groups might occur. For example, marketing and patient demand drove the early adoption of RARP and it was demonstrated that white and Asian men and those residing in areas of higher household income and education were more likely to elect RARP over ORP. 3 Despite adjusting for race and sociodemographic differences in our study, men opting for RARP may be more likely to follow healthier lifestyles, such as exercising and avoiding smoking, which is not captured by SEER-Medicare.
Our study does have some limitations. We are unable to characterize post-radical prostatectomy PSA values. In addition, there is significant provider heterogeneity in the administration of additional treatment after prostatectomy, 36 particularly across varied practice settings. 37 However, our use of additional ADT and radiation therapy as a surrogate for cancer control proves effective because both are independently associated with worse prostate cancer specific survival. Our study is also limited to elderly Medicare beneficiaries, who may be less likely to receive additional therapy given the associated morbidity and competing mortality risks with advancing age. In addition, there may be underestimation of the benefit of RARP on survival as some hospitals may incorrectly record the administrative code for designating robot-assisted surgery. Thus, some RARP may be misclassified as ORP. In addition, inherent with observational study, there may be residual confounding that cannot be addressed by study design and analysis. However, sensitivity analysis showed little change to outcomes. Recent criticisms of SEER population data in regard to evaluating outcomes in PCa focus on a lack of granularity as prostate specific metrics, such as PSA and Gleason score, are not available or are unreliable. However, the largest shift in stage, seen with the introduction of the AJCC 7th edition at the beginning of 2010, would lead to an underestimation of the effectiveness of RARP. 38 There have been changes to Gleason score as well over time, which has also impacted stage migration within this cohort.
Our study has several important implications from an oncologic and global health perspective. While the adoption of RARP was not evidencebased, the noninferior intermediate-term survival in this population should be reassuring for critics. The reduction in additional cancer therapies associated with RARP is likely to offset the criticism of higher costs for robotic vs open surgery and stretch the benefits of RARP beyond perioperative advantages of lower blood loss, fewer transfusions and anastomotic strictures, shorter hospitalizations and lower 30-day mortality. 
CONCLUSIONS
RARP is associated with less use of postoperative ADT and radiation therapy, and equivalent prostate cancer specific and all cause mortality. This is reassuring and should lead to better health care decisions in the absence of robust comparative data for a procedure that has serious quality and cost implications.
